Showing 5 ideas for tag "kidney"

Goal 2: Reduce Human Disease

Optimization of Existing Therapies for Sickle Cell Disease

How can the safety, dosing and benefits of existing therapies for sickle cell disease such as hydroxyurea, be optimized in order to increase its efficacy and improve patient adherence?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Hydroxyurea is a widely available disease-modifying therapy for sickle cell disease (SCD), but its effectiveness is currently limited by inadequate utilization, and less than optimal response. Research is needed to improve adherence to this evidence-based therapy and emphasis needs to be placed on determining whether therapy with hydroxyurea can prevent or even reverse organ dysfunction. In addition, research identifying new adjunct therapies to blood transfusion and hydroxyurea, as well as disease-specific therapies for co-morbidities such as kidney disease, hypertension, obstructive lung disease, and pulmonary hypertension will be valuable in the management and treatment of SCD.

Name of idea submitter and other team members who worked on this idea Alice Kuaban on behalf of the American Society of Hematology (ASH)

Voting

54 net votes
74 up votes
20 down votes
Active

Goal 2: Reduce Human Disease

Implications of Sickle Cell Trait

What are the healthcare implications of sickle cell trait?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Millions of people in the U.S and throughout the world have sickle cell trait, yet other than its impact on athletes and the recent finding that it may significantly raise the risk of chronic kidney disease, little is known about the trait’s effect on the health of those who carry it. Additional research is needed to further elucidate the implications of sickle cell trait alone, in combination with other genetic tendencies or in response to certain environmental factors. Findings can be used to provide evidence-based clinical guidance for the millions of people who may be affected

Feasibility and challenges of addressing this CQ or CC

Addressing this question is feasible. Obtaining sufficient long-term data to answer these questions may be challenging.

Name of idea submitter and other team members who worked on this idea The Sickle Cell Association of New Jersey

Voting

6 net votes
6 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

What is the optimal management of coronary artery disease in patients with chronic kidney disease

Patients with chronic kidney disease (CKD) have an extremely high risk of death from cardiovascular cause. The prognosis of patients with chronic kidney disease who also have coronary artery disease is worse than certain cancer. While great strides have been made to create awareness about breast cancer, there is paucity of knowledge about the cardiovascular risk of CKD patients among both physicians and patients. Moreover,... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Patients with chronic kidney disease tend to be undertreated (from CV perspective), underrepresented (in clinical trials) and underdiagnosed with less referral for stress testing, even though cardiovascular cause is the leading cause of death in these patients. Patients with chronic kidney disease is a growing cohort and with increase in obesity and diabetes, the prevalence is exploding exponentially. The decision as to what is the best treatment option for patients with coronary artery disease who also have kidney disease- revascularization or medical therapy-is important and can be a paradigm shift in the way we treat such patients

Feasibility and challenges of addressing this CQ or CC

Randomized clinical trials are urgently needed to answer this question.

Name of idea submitter and other team members who worked on this idea Sripal Bangalore

Voting

0 net votes
9 up votes
9 down votes
Active

Goal 3: Advance Translational Research

Finding Why Apolipoprotein L1 Gene Variants Increase the Risk for Kidney Failure in African Americans

We plan to find the role of APOL1 in increasing the risk of kidney failure in African Americans and translate this knowledge into preventing end-stage kidney disease and the need for kidney replacement therapy, dialysis or kidney transplantation.

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Critical Challenge (CC)

Details on the impact of addressing this CQ or CC

Increase the quality of life for millions by preventing end-stage kidney disease and thus saving billions of dollars.

Name of idea submitter and other team members who worked on this idea Carey Green MD, Dollie Green MD

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Repair and Regenerate the Kidney

Chronic Kidney Disease (CKD) affects millions in the US, and is one of the new diseases on the rise globally. New therapies to slow CKD and to repair and regenerate failing kidneys are drastically needed to reduce health care costs and improve lives.

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Critical Challenge (CC)

Details on the impact of addressing this CQ or CC

New therapies to slow CKD and to repair and regenerate failing kidneys are sorely needed to reduce health care costs and improve lives.

Feasibility and challenges of addressing this CQ or CC

Our understanding of renal function and risk factors is greater than ever. Our ability to diagnose is technologically advanced. We now need to increase efforts to identify therapeutic targets and develop regenerative approaches to prevent and treat CKD.

Name of idea submitter and other team members who worked on this idea Ceci Giachelli

Voting

1 net vote
1 up votes
0 down votes
Active